SCHEDULE 13G: Dauntless Investment Group Discloses 5.87% Passive Stake in OKYO Pharma Ltd

Dauntless Investment Group, LLC has filed a Schedule 13G, disclosing a passive beneficial ownership of 1,999,380 common shares, representing 5.87% of OKYO Pharma Ltd.

Summary

• Dauntless Investment Group, LLC reported beneficial ownership of 1,999,380 common shares of OKYO Pharma Ltd.
• This stake represents 5.87% of OKYO Pharma Ltd.'s common stock.
• The filing indicates a passive investment, meaning the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
• Dauntless Investment Group, LLC is classified as a Single Family Office/Passive Investor.
• The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934.

Sentiment

Score: 5

Explanation: Neutral. A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook. It simply reports a passive stake.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by an institutional investor like Dauntless Investment Group, LLC may be viewed by existing and potential shareholders as a positive signal of confidence in OKYO Pharma Ltd, potentially influencing market perception.

Key Dates

Keywords

OKYO Pharma Ltd, Dauntless Investment Group, Schedule 13G, Beneficial Ownership, Passive Investment, Common Stock, SEC Filing